文献速递流行病学与生物统计新药、器械与细胞基因治疗研发

SGLT2抑制剂在1型糖尿病中酮症酸中毒风险的荟萃分析与元回归

Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
PubMed 文献 · PLoS Med · 2020-12-29

该荟萃分析纳入18项安慰剂对照随机试验(7396例1型糖尿病患者),评估SGLT2抑制剂相关酮症酸中毒(DKA)风险及疗效的调节因素。多变量元回归显示基线BMI和估算葡萄糖处置率(eGDR)与DKA相对风险相关,联合治疗相关参数可解释86%的DKA风险变异。SGLT2抑制剂还降低白蛋白尿和糖尿病眼病风险。

要点

  • 基线BMI和胰岛素抵抗指标可预测SGLT2抑制剂相关DKA风险。
  • BMI>27 kg/m2和eGDR<8.3 mg/kg/min与DKA风险升高相关。
  • SGLT2抑制剂可降低白蛋白尿和糖尿病眼病风险。

核心结论

  • 在1型糖尿病患者中,SGLT2抑制剂相关DKA风险及主要疗效受基线BMI、胰岛素抵抗、胰岛素剂量变化与基线胰岛素敏感性比值及容量不足影响。

研究设计与样本

  • 荟萃分析与元回归,纳入18项安慰剂对照随机对照试验,共7396例成年1型糖尿病患者,平均年龄42岁,评估5种SGLT2抑制剂。

主要发现

  • 多变量元回归中,基线BMI(β=0.439,95%CI 0.211-0.666,p<0.001)和eGDR(β=-0.766,95%CI -1.276至-0.256,p=0.001)与DKA相对风险相关(总体RR=2.81,95%CI 1.97-4.01,p<0.001,R2=61%)。
  • 包含治疗相关参数的模型解释86%的DKA风险变异(R2=86%)。
  • SGLT2抑制剂降低白蛋白尿(WMD=-9.91,95%CI -16.26至-3.55 mg/g,p=0.002)和糖尿病眼病风险(RR=0.27,95%CI 0.11-0.67,p=0.005)。
  • 主要疗效结局呈SGLT2抑制剂剂量反应梯度,但不良事件无此梯度。

关键数值与推荐

  • BMI>27 kg/m2和eGDR<8.3 mg/kg/min与DKA风险升高相关,在亚组分析中得到确认。

临床怎么用

  • 基线BMI和胰岛素抵抗指标可能有助于选择SGLT2抑制剂治疗获益最大且DKA风险最低的1型糖尿病患者。

局限性

  • 纳入的随机对照试验持续时间较短(≤52周)。
  • 临床实践相关性需真实世界前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sodium-glucose cotransporter-2 (SGLT2) inhibitors (SGLT2i) showed benefits in type 1 diabetes mellitus (T1DM), but the risk of diabetic ketoacidosis (DKA) limits their use. Ability to predict DKA risk and therapeutic responses would enable appropriate patient selection for SGLT2i. We conducted a meta-analysis and meta-regression of randomized controlled trials (RCTs) evaluating SGLT2i in T1DM to assess moderators of the relative risk (RR) of DKA, of glycemic (HbA1c, fasting plasma glucose, continuous glucose monitoring parameters, insulin dose, and insulin sensitivity indices) and non-glycemic (body mass index (BMI), systolic BP, renal function, albuminuria, and diabetic eye disorders) efficacy, and of other safety outcomes (including hypoglycemia, infections, major adverse cardiovascular events, and death). METHODS AND FINDINGS: We searched MEDLINE, Cochrane Library, EMBASE, ClinicalTrials.gov, Cochrane CENTRAL Register of Controlled Trials, and other electronic sources through August 30, 2020, for RCTs comparing SGLT2i with active comparators or placebo in adult patients with T1DM. Reviewers extracted data for relevant outcomes, performed random effects meta-analyses, subgroup analyses, and multivariable meta-regression. The strength of evidence was summarized with the GRADE approach. Among 9,914 records identified, 18 placebo-controlled RCTs (7,396 participants, 50% males, mean age 42 y (range 23 to 55 y), 5 different SGLT2i evaluated), were included. Main outcome measures were effect sizes and moderators of glycemic and non-glycemic efficacy and of safety outcomes. In a multivariable meta-regression model, baseline BMI (β = 0.439 [95% CI: 0.211, 0.666], p < 0.001) and estimated glucose disposal rate (eGDR) (β = -0.766 [-1.276, -0.256], p = 0.001) were associated with the RR of DKA (RR: 2.81; 95% CI:1.97, 4.01; p < 0.001, R2 = 61%). A model including also treatment-related parameters (insulin dose change-to-baseline insulin sensitivity ratio and volume depletion) explained 86% of variance across studies in the risk of DKA (R2 = 86%). The association of DKA with a BMI >27 kg/m2 and with an eGDR <8.3 mg/kg/min was confirmed also in subgroup analyses. Among efficacy outcomes, the novel findings were a reduction in albuminuria (WMD: -9.91, 95% CI: -16.26, -3.55 mg/g, p = 0.002), and in RR of diabetic eye disorders (RR: 0.27[0.11, 0.67], p = 0.005) associated with SGLT2i. A SGLT2i dose-response gradient was consistently observed for main efficacy outcomes, but not for adverse events (AEs). Overall, predictors of DKA and of other AEs differed substantially from those of glycemic and non-glycemic efficacy. A limitation of our analysis was the relatively short (≤52 weeks) duration of included RCTs. The potential relevance for clinical practice needs also to be confirmed by real-world prospective studies. CONCLUSIONS: In T1DM, the risk of DKA and main therapeutic responses to SGLT2i are modified by baseline BMI and insulin resistance, by total insulin dose reduction-to-baseline insulin sensitivity ratio, and by volume depletion, which may enable the targeted use of these drugs in patients with the greatest benefit and the lowest risk of DKA.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Musso G, Sircana A, Saba F, et al. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression. PLoS Med. 2020. PMID: 33373368. doi:10.1371/journal.pmed.1003461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。